Evidence map›Paper›PMID 27432838›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2016

Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.

Colin J Forsyth, Salvador Hernandez, Wilman Olmedo, Adieb Abuhamidah, Mahmoud I Traina, Daniel R Sanchez, Jonathan Soverow, Sheba K Meymandi

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 115 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Chagas disease in immunocompromised patients.Clinical microbiology reviews · 2024
    Review
  14. Article
  15. Article
  16. Chagas Disease.Annals of internal medicine · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Colin J ForsythCenter of Excellence for Chagas Disease, Olive View-University of California, Los Angeles Medical Center, Sylmar.
Salvador HernandezCenter of Excellence for Chagas Disease, Olive View-University of California, Los Angeles Medical Center, Sylmar.
Wilman OlmedoCenter of Excellence for Chagas Disease, Olive View-University of California, Los Angeles Medical Center, Sylmar.
Adieb AbuhamidahCenter of Excellence for Chagas Disease, Olive View-University of California, Los Angeles Medical Center, Sylmar.
Mahmoud I TrainaCenter of Excellence for Chagas Disease, Olive View-University of California, Los Angeles Medical Center, Sylmar.
Daniel R SanchezCenter of Excellence for Chagas Disease, Olive View-University of California, Los Angeles Medical Center, Sylmar.
Jonathan SoverowCenter of Excellence for Chagas Disease, Olive View-University of California, Los Angeles Medical Center, Sylmar.
Sheba K MeymandiCenter of Excellence for Chagas Disease, Olive View-University of California, Los Angeles Medical Center, Sylmar.
Los Angeles Medical Center · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNifurtimox is 1 of only 2 medications available for treating Chagas disease (CD) and currently the only drug available in the United States, but its safety and tolerance have not been extensively studied. This is the first study to evaluate tolerance of nifurtimox in US patients with CD.

methodsThis investigation assessed side effects in a sample of 53 patients with CD, all Latin American immigrants, who underwent treatment with nifurtimox (8-10 mg/kg in 3 daily doses for 12 weeks) from March 2008 to July 2012. The frequency and severity of adverse events (AEs) was recorded.

resultsA total of 435 AEs were recorded; 93.8% were mild, 3.0% moderate, and 3.2% severe. Patients experienced a mean of 8.2 AEs; the most frequent were anorexia (79.2%), nausea (75.5%), headache (60.4%), amnesia (58.5%), and >5% weight loss (52.8%). Eleven patients (20.8%) were unable to complete treatment. Experiencing a moderate or severe AE (odds ratio [OR], 3.82; P < .05) and Mexican nationality (OR, 2.29; P < .05) were significant predictors of treatment discontinuation, but sex and cardiac progression at baseline were not. Patients who did not complete treatment experienced nearly 3 times more AEs per 30-day period (P = .05).

conclusionsNifurtimox produces frequent side effects, but the majority are mild and can be managed with dose reduction and/or temporary suspension of medication. The high frequency of gastrointestinal symptoms and weight loss mirrors results from prior investigations. Special attention should be paid during the early stages of treatment to potentially severe symptoms including depression, rash, and anxiety.

Indexed as

AdultAgedChagas DiseaseDrug-Related Side Effects and Adverse ReactionsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNifurtimoxPhenotypeRisk FactorsSeverity of Illness IndexSymptom AssessmentTreatment OutcomeTrypanocidal AgentsNifurtimoxTrypanocidal AgentsbenznidazoleChagas diseasenifurtimoxside effectsTrypanosoma cruzi

Identifiers

PMID27432838
PMCPMC5036918
OpenAlexW2488219907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.